News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • CoreWeave reports a $104.2B backlog and raised 2026 revenue guidance, signaling sustained demand for AI infrastructure.
  • Elevated interest costs and a stretched balance sheet limit CoreWeave's margins and raise execution risk.
  • UnitedHealth's improving medical-cost trends and stronger Optum performance support a recovery trade thesis.
  • UnitedHealth trades below key moving averages despite $23.6B free cash flow and rising earnings estimates.
  • Century Therapeutics faces competitive erosion of its iPSC edge, making it a high-risk short ahead of binary readouts.

Latest Articles

RingCentral Director Amy Shenkan Executes Rule 10b5-1 Sale of 1,265 Shares

RingCentral Director Amy Shenkan Executes Rule 10b5-1 Sale of 1,265 Shares

RingCentral, Inc. (NASDAQ: RNG) director Amy Guggenheim Shenkan sold 1,265 shares of the company's Class A Common Stock on July 2, 2026, realizing $51,350 from the transaction. The sale was executed under a pre-established Rule 10b5-1 trading plan adopted in August 2025, a mechanism designed to facilitate compliance with insider trading regulations…

Cerus CEO William Greenman Executes Pre-Arranged Stock Sale

Cerus CEO William Greenman Executes Pre-Arranged Stock Sale

Cerus Corporation (NASDAQ: CERS) President and CEO William Greenman completed a series of stock transactions on June 30, 2026, resulting in the sale of common stock valued at approximately $299,937. The transactions were executed under a Rule 10b5-1 plan to satisfy statutory tax withholding and brokerage fees associated with the vesting of restrict…

Nektar Therapeutics R&D Chief Sells $397,670 of Common Stock

Nektar Therapeutics R&D Chief Sells $397,670 of Common Stock

Jonathan Zalevsky, Chief R&D Officer at Nektar Therapeutics (NASDAQ:NKTR), executed a sale of 5,681 shares of common stock on June 30, 2026, totaling $397,670. The transaction, conducted at $70.00 per share, was carried out under a pre-established Rule 10b5-1 trading plan adopted in March 2026. Following the sale, Zalevsky retains direct ownership …

Stem CEO Narayanan Executes Automatic Stock Sale to Cover Tax Obligations

Stem CEO Narayanan Executes Automatic Stock Sale to Cover Tax Obligations

Stem Inc. CEO Arun Narayanan completed a mandatory stock sale on July 2, 2026, to satisfy tax liabilities arising from the vesting of performance stock units. The transaction occurred as the stock trades near its 52-week low, though recent operational developments highlight the company’s focus on AI integration and energy management systems within …

ON Semiconductor: Mispriced Bet on 800V-1200V AI Power and Physical AI

ON Semiconductor: Mispriced Bet on 800V-1200V AI Power and Physical AI

ON Semiconductor recently sold off after the $7B Synaptics deal and dilution headline. The market has focused on near-term dilution while under-appreciating two durable, higher-margin end markets forming around 800V-1200V silicon carbide power for AI data centers and the Physical AI transition at the edge. ON's balance sheet, cash flow generation a…

Neurogene CFO Cvijic Offloads $166K in Shares Amid Biotech Sector Shifts

Neurogene CFO Cvijic Offloads $166K in Shares Amid Biotech Sector Shifts

Neurogene Inc. (NASDAQ:NGNE) President and Chief Financial Officer Christine Mikail Cvijic sold a total of 4,800 shares of the company's common stock between July 1 and July 2, 2026. The transactions, valued at approximately $166,586, were conducted under a Rule 10b5-1 trading plan established in August 2025. The sale occurred as Neurogene's stock …

Buy the Capability, Not the Profits: A Tactical Long on Voyager (VYGR)

Buy the Capability, Not the Profits: A Tactical Long on Voyager (VYGR)

Voyager Therapeutics has moved beyond single-program risk into a platform story: new AAV capsids that penetrate the blood-brain barrier, multiple Alzheimer’s-focused assets, and a stretched but still visible cash runway. The technicals and short-interest dynamics make a defined-risk long trade attractive over the next ~45 trading days, but executio…

Ormat Technologies Executive Divests Shares Amid Geothermal Expansion

Ormat Technologies Executive Divests Shares Amid Geothermal Expansion

Ormat Technologies Inc. (NASDAQ: ORA) Executive Vice President Aron John Willis executed a transaction involving the sale of 451 shares on July 1, 2026. The divestiture, totaling $48,094, was structured to satisfy tax withholding obligations associated with the vesting of restricted stock units. This event occurs against a backdrop of operational e…

Massive Overnight Assault Leaves Kyiv Reeling; At Least 27 Dead, Hundreds Injured

Massive Overnight Assault Leaves Kyiv Reeling; At Least 27 Dead, Hundreds Injured

Hundreds of unmanned aerial vehicles and dozens of missiles struck Kyiv in the early hours of Thursday, killing at least 27 people, wounding scores and damaging about 130 buildings across the city. Ukrainian officials say the attack - which involved an unusually large number of ballistic missiles and a low interception rate - is the deadliest on th…